Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to ...

Shares of biopharma company Viking Therapeutics ($VKTX) rose as high as 5% during the first hour of trading on Monday. The ...

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $28.60, representing a 15.98% upside. In a report released today, J.P. Morgan also maintained a Hold rating on the ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $30.00. The company’s shares closed yesterday at $24.66. Take advantage of TipRanks Premium at 50% ...

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

If you’re after reliable dividend income, dividend aristocrats should be on your radar — they are companies with impressive ...

At a margin of 40%, Palantir delivered $476 million net income (GAAP). Overall, the company now has $6.4 billion in cash and cash equivalents. More importantly for investors, Palantir raised its FY ...

The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...

Stock futures pointed higher following a down week, as investors were optimistic a deal was near to end the record U.S. government shutdown.